Sabin-IPV and DTaP

BIOLOGICAL2 trials

Sponsors

China National Biotec Group Company Limited

Conditions

Vaccination

Phase 4

Clinic Trial to Evaluate the Safety and Immunogenicity of Combined Immunization of sIPV and DTaP

China National Biotec Group Company LimitedVaccination

Start: 2019-08-10End: 2020-05-30Target: 702Updated: 2019-08-12

Evaluation of the Safety and Immunogenicity of Simultaneously Administration of sIPV and DTaP

CompletedNCT04054882

China National Biotec Group Company LimitedVaccination

Start: 2019-08-16End: 2021-09-09Updated: 2022-07-07

Related Papers

Immunogenicity and safety of co-administration of sabin-strain-based inactivated poliovirus vaccine, diphtheria-tetanus-acellular pertussis vaccine, and live attenuated hepatitis A vaccine in 18-month-old children: A multicenter randomized controlled non-inferiority trial in China.

2025-10-27

Immunogenicity and safety of co-administration with the Sabin-strain-based inactivated poliovirus vaccine (vero cell) and the diphtheria-tetanus-acellular pertussis vaccine in eligible children in China: a randomized, controlled, multicenter, non-inferiority trial

Frontiers in Immunology2025-09-03

Immunogenicity and safety of concomitant administration of the chinese inactivated poliovirus vaccine with the diphtheria-tetanus-acellular pertussis (DTaP) vaccine in children: A multicenter, randomized, non-inferiority, controlled trial

Frontiers in Immunology2022-07-269 citations